Home
Antibodies
Cervical Cancer
Our Company
News
Contact Us
International Distributors
Ordering List
Home
Antibodies
Cervical Cancer
Our Company
News
Contact Us
Home
>
Our Company
Our Company
Precision medicine starts with precision diagnostics – this is the core belief of GenomeMe. Since its inception in 2015, GenomeMe has been developing and commercializing novel IVD tools for the detection, characterization and prognosis of cancer in order to make precision medicine more accessible.
Our Awards
The Life Sciences industry is booming in Canada. We are honoured to share the title of
13th Biggest Life Science Company in British Columbia
with Alectos Therapeutics, BioLytical Laboratories, and Kinexus Bioinformatics Corp in 2017. We are proud to be a part of this fast growing medical innovation community
GenomeMe was recognized as the
19th Biggest Life Science Company in British Columbia
in 2016 by Business in Vancouver Magazine and Life Science BC. Thank you very much for this honor!
Our Certifications
Our newly renovated 9,000 sqf facility located in Vancouver, BC is CMD/CSA ISO 13485:2003 and EN ISO 13485:2012 certified to bring the highest standards of safety and quality to every product and service we offer no matter where in the world you are.
CMD/CAS ISO 13485:2003
EN ISO 13485:2012
Our Technology
We use the most powerful DNA sequencing and quantification technologies currently on the market to develop products and services to make tomorrow’s healthcare solutions available today.
qPCR Technology
We use qPCR technology to zero in on pathogens and single gene mutations. The qPCR platform is our strategy for HPV detection and the technology behind many of the kits currently in our pipeline for other major infectious diseases such as
Brucella
bacteria and Norovirus detection.
×
Next Generation Sequencing
Next Generation Sequencing technology reads billions of DNA strands simultaneously, making it so powerful it can read your entire genetic story in just a few days.
×
Automated IHC Stainer
Automation is the key ingredient guaranteeing quality, reproducibility and reliability in a fast paced environment. By utilizing this technology for IHC staining we are able to screen, validate, and QC our entire Molecular Pathology portfolio - providing superior quality at a fraction of the cost.
×
×
